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Abstract: Pharmacotherapies for schizophrenic and cocaine psychoses are complex but similar 
because of similarities in their brain neurochemistry and behavioral outcomes. Their neuro-
chemical neuronal mechanisms of action, as shown in preclinical and clinical studies, involve 
primarily dopaminergic dysfunction and, secondarily, neuroadaptive effects that seem to involve 
central serotonergic function. Behavioral outcomes of both disorders include hyperactivity and 
antipsychotic medications can ameliorate psychotic symptoms. Patients with both disorders 
often arrive at emergency departments and present ﬂ oridly psychotic with a predominance of 
positive symptoms, often prompting physicians to select a typical antipsychotic medication such 
as haloperidol. While this has become conventional wisdom, we believe that to use an atypical 
antipsychotic medication, such as risperidone, in the treatment of both psychoses is quite rational 
for long-term management of both positive and negative symptoms. Also, controlled clinical 
studies have shown that risperidone, an atypical antipsychotic medication, is successful in the 
treatment of cocaine dependence and withdrawal (Smelson et al 1997, 2002; Grabowski et al 
2000). Furthermore, the availability and effectiveness of long-acting risperidone in injectable 
form opens new possibilities for the long-term management of both disorders. In this paper, we 
present data which show that the use of risperidone is plausible for effective pharmacotherapy 
of schizophrenic and cocaine psychoses. 
Keywords: schizophrenia, cocaine psychosis, psychopharmacotherapy, typical antipsychotic, 
atypical antipsychotic, risperidone
Introduction
The treatment of schizophrenic psychosis demands complex solutions encompassing 
the multiplicity of variables associated with its onset, psychoneurobiology, course, 
and prognosis. The same can be said of cocaine psychosis. The following are clini-
cal observations that underscore the relationship between schizophrenic and cocaine 
psychoses: (1) psychostimulants can produce psychotic syndromes in normal subjects; 
(2) psychostimulants at doses which would not be psychotogenic in normal subjects, 
exacerbate psychotic symptoms in a majority of schizophrenic patients; (3) stress 
precipitates psychotic behavior (Yui et al 1999); and (4) psychostimulants have been 
shown to produce positive psychotic symptoms in neuroleptic-naïve schizophrenic 
patients (Hietala et al 1995).
Indeed, similarities between and co-morbidity of schizophrenic and cocaine 
psychoses appear over and again in the clinical literature over the last two decades 
(Brady et al 1991; Serper et al 1999; Harris and Batki 2000; Green et al 2004; Cubells 
et al 2005; Mauri et al 2006). For example, Cubells and colleagues (2005) have 
reported that cocaine induces a psychotic syndrome, which is transient, delusional 
and hallucinatory and covaries with the severity of cocaine-induced psychotic para-
noia. Serper and colleagues (1999) have shown that behavior in patients with cocaine 
intoxication and then acute abstinence mimics the positive and negative symptoms 
of schizophrenia. Clinical data show that about 50% of the patients who suffer from 
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schizophrenia have also been substance abusers at some time 
during their illness and that schizophrenic patients often feel 
the need to alleviate psychosis by using reinforcing drugs 
(cf. Buckley 1998). Moreover, cocaine-abusing patients 
are more likely to be diagnosed with schizophrenia of the 
paranoid subtype and to exhibit more negative symptoms in 
the schizophrenic psychotic syndrome than do non-substance 
abusing patients (Lysaker et al 1994). In addition, Green 
and colleagues (1999) have provided additional data that 
show that the atypical antipsychotic medication, clozapine, 
is beneﬁ cial for patients with comorbid substance use and 
schizophrenia. 
Particularly relevant to the relationship between 
schizophrenic and cocaine-induced psychosis are biochemical 
data which show that both disorders are remarkably similar 
in their neurochemical neuronal mechanism of action. Pre-
clinical and clinical studies show that both disorders involve 
primary dopaminergic dysfunction and that secondary 
neuroadaptive effects seem to involve central serotonergic 
function. Furthermore, concomitant behavioral outcomes for 
both disorders include hyperactivity (Broderick and Phelix 
1997; Angelopoulos et al 2002; Carlsson and Carlsson 
2006). 
Solutions for these related psychoses must address as 
many facets of these disorders as necessary, and at least 
include psychopharmacotherapy and appropriate psycho-
therapies. In this paper, we address psychopharmacother-
apy, particularly research relating to the neuroscience and 
therapeutics of antipsychotic agents and their applications 
in schizophrenia and cocaine psychosis and abuse. Further, 
we highlight salient points of this research together with 
mechanisms and hypotheses published by other researchers, 
and present illustrative clinical cases. 
Schizophrenia: an overview
Schizophrenia, a chronic and debilitating disorder that usu-
ally manifests in late adolescence and young adulthood, is 
the prototypical psychosis, a term that refers to behavior, ie, 
symptoms and signs, that breaks from consensual reality. 
Schizophrenia impairs several areas of brain functioning, 
but especially 1) cognition (form and content of thought, 
attention and concentration, insight, and judgment), 2) per-
ception, 3) emotions, and 4) behavior (Andreasen 1987). It 
is a major medical problem by any measure, present in all 
cultures, and has been described in writings going back to 
the 12th century BC. With lifetime prevalence in the United 
States ranging from 1% to 2%, schizophrenia accounts for 
over 2.5% of all medical expenditures, or about 50 billion 
dollars a year. Patients with schizophrenia occupy about 
50% of all mental hospital beds and comprise about 16% 
of all psychiatric patients who receive treatment, two thirds 
of whom need hospitalization. Yet only about half of all 
schizophrenics receive treatment regardless of illness sever-
ity. Schizophrenia often has serious individual and social 
consequences and its emotional cost to patients and loved 
ones is immeasurable.
Although etiological factors underlying the disorder 
have not yet been fully elucidated, we accept the under-
standing that predominantly biological factors, including 
genetic predisposition, transact with adverse environmental, 
social, and psychological factors to create, precipitate, and 
perpetuate the disorder. Findings such as neuroimaging 
evidence of mesocorticolimbic decreased prefrontal cortex 
activity and the precipitating and perpetuating power of ex-
pressed emotions, stressful life events, and social downdrift 
corroborate this view (Verhoeff et al 2000). Furthermore, 
the well-known dopamine hypothesis of schizophrenia, 
dopaminergic hyperfunction in mesolimbic areas of the 
brain (Stahl 2000), is now supported by direct evidence from 
single photon emission computed tomography (SPECT), 
wherein the unchallenged release of dopamine is elevated 
in schizophrenic patients compared with controls (Abi-
Dargham et al 2000). Dopamine D2 receptor occupancy 
is critical to dose and to differences between typical and 
atypical antipsychotic medication (Naikar et al 2006). 
Finally, this hyperdopaminergic function in schizophrenia 
may be accompanied by decreased glutamate function 
(Kegeles et al 2000).
Arvid Carlsson’s group in Sweden has been conducting 
pioneering research in schizophrenia, developing antipsychotic 
compounds called “dopamine stabilizers” (stabilizers), which 
are capable of ameliorating schizophrenia symptoms without 
producing side effects (Rung et al 2005; Nilsson et al 2006). 
These dopamine stabilizers preferentially target extrasynaptic 
receptors while leaving synaptic transmission and basic dopa-
mine function intact. Ohara (2007) has reported a further addi-
tion to the dopamine hypothesis of schizophrenia by showing 
that an n-3 fatty acid deﬁ ciency can lead to reduced dopamine 
concentration, number of dopamine vesicles and dopamine 
(D2) receptors at prefrontal presynaptic terminals. 
Serotonin, a secondary neuroadaptive mechanism in 
schizophrenia, (Angelopoulos et al 2002) balances dopamine 
in mesolimbic and mesocorticolimbic structures in the brain. 
This dopamine-serotonin balance provides the leading 
hypothesis for the mechanism of action of atypical antipsy-
chotic medications. 
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Advanced paternal age has been demonstrated to be more 
prevalent in the history of persons with schizophrenia than in 
that of unaffected persons, which Malaspina and colleagues 
(2002) suggest, owes to the possibility of de novo muta-
tions in paternal germ cells. Age of onset is earlier for men 
compared to women even though both sexes end up being 
equally affected. Prenatal viral infections and exposure to 
certain drugs such as diuretics (Sorensen et al 2003) have 
also been implicated in the etiology of schizophrenia. The 
ﬁ nding that more people with the disorder are born in the 
cold months (Smits et al 2004) suggests that viral infection, 
which can affect fetal brain development, particularly during 
the 2nd gestational trimester, may be another causative factor. 
Unknown developmental factors which may cause schizo-
phrenia in later years may be due to increased dopaminergic 
tone as opposed to hyperdopaminergic function (Carlsson 
and Carlsson 2006). 
Historically, Bleuler (1911) referred to the schizophrenic 
disorder in the plural, perhaps already glimpsing its heteroge-
neity and probable etiological multiplicity. While the uncer-
tainties remain, today we speak of schizophrenia as a brain 
disorder, and we understand it better as a psychotic syndrome 
whose signs and symptoms we treat. Thus, its distinguishing 
features are grouped into two categories: positive symp-
toms, an exaggeration of normal functioning, and negative 
symptoms, a deﬁ cit in normal functioning. Thinking that is 
disordered both in form and content, conveyed by disordered 
speech, and hallucinations that are primarily auditory count 
among the positive symptoms. Andreasen (1982) listed the 
following negative symptoms: Affective ﬂ attening, alogia, 
avolition, anhedonia, and attentional deﬁ cits. Although 
positive symptoms are often ﬂ orid, dramatic, and demand 
immediate attention, while negative symptoms are insidi-
ous and low key, both categories can seriously disrupt the 
person’s life, markedly diminishing its quality. Negative 
symptoms have always been more difﬁ cult to treat, often 
understood as intractable proof of social downdrift.
Pharmacology of antipsychotic 
medications
Typical and atypical antipsychotic medications differ in 
side effect proﬁ le because they also differ signiﬁ cantly in 
mechanism and site of action of therapeutic effect. Regard-
ing side effect proﬁ le, one ought to bear in mind that the 
medication must be effective for its intended purpose and that 
its beneﬁ ts must outweigh its risks. Typical antipsychotics 
such as haloperidol that readily resolve positive symptoms, 
are seemingly ineffective in the treatment of negative 
symptoms of psychosis (Carpenter et al 1988). The advent 
of the atypical antipsychotics brought the reversal of both 
symptom categories within range (Meltzer 1992; Conley and 
Mahmoud 2001). This effectiveness led to important adjust-
ments in our understanding of the mechanisms of action of 
both drug categories. Typicals control positive symptoms 
through their action as dopamine antagonists presumably 
through high occupancy of dopamine D
2
 receptors in the 
nigrostriatum (Farde et al 1988; Mukherjee et al 2001), an 
action that can also produce anhedonia (Blum et al 1989) and 
extrapyramidal side effects (EPS). Typicals have little effect 
on serotonergic mechanisms (Broderick and Piercey 1998; 
Ichikawa et al 1998). Conversely, atypicals act primarily 
but not exclusively, on serotonin
2
/dopamine
2
 receptors in 
mesocorticolimbic neurons to reduce positive and negative 
symptoms, with little risk of EPS, likely due to serotonergic 
modulation of dopamine (Meltzer and Nash 1991). The 
serotonergic function of atypical antipsychotic medications 
may also account for their effect of improving anhedonia and 
affective disorders, as Meltzer (1989) reported.
Pharmacological behavioral studies in animal models also 
provide a means of demonstrating differences between typi-
cal and atypical antipsychotics. Typicals inhibit hyperactivity 
and stereotypy induced by administration of dopaminergic 
drugs. They also produce catalepsy in similar dose ranges. 
Under similar circumstances, atypicals selectively inhibit 
hyperactivity without inducing catalepsy (Weiner et al 2000; 
Wadenberg et al 2001). In animal models, perospirone, a 
model serotonin
2
/dopamine
2
 receptor antagonist, contrary 
to typicals, showed preferential ability to induce Fos protein 
expression in the mesolimbic nucleus accumbens versus 
nigrostriatal dorsolateral terminal (Ishibashi et al 1999).
Schizophrenia: a clinical case
Anthony came to the psychiatrist’s ofﬁ ce referred by his 
primary care physician. He came accompanied by his mother 
and appeared inordinately passive and dependent on her, 
which appeared incongruous for an 18-year-old male. The 
mother told the story; he often nodded in agreement. 
He had gone to an Army boot camp in Virginia, just 
days after his 18th birthday, 8 months before the doctor 
visit. A month before the visit, he called the mother from 
the Port Authority Bus Terminal in Midtown Manhattan, 
New York City, and asked her to come pick him up. They 
lived an easy half-hour subway ride away, in Queens, 
another New York City borough. He had been used to 
traveling around the entire city and knew it “like the back 
of his hand,” so the mother was alarmed when he claimed 
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he did not know how to get home or what to do. To the 
mother, Anthony sounded like a broken man and she was 
“shocked and worried sick.” She found him sitting on an 
overstuffed duffel bag looking lost, eyes gazing into noth-
ingness. Expressionless, he stood up and remained halfway 
between limp and stiff as she hugged him and cried. He 
asked her not to cry, saying he was ﬁ ne. When asked why 
he had returned, he said he could not talk about it because 
he was under surveillance. He claimed his thoughts and 
his every move were being monitored and that he was in 
grave danger. He asserted that he needed to refrain from 
speaking. He showed her, in a bizarrely secretive way, 
what amounted to his discharge papers from a psychiatric 
ward in a hospital close to the base, where he had been 
kept as an inpatient for most of the previous month. He 
whispered he was going to have a dishonorable discharge 
from the Army. Later he told his mother he had punched an 
ofﬁ cer who forced him to do night duty in “a clear effort” 
to get him killed. He “defended” himself to avoid getting 
killed, prompted by voices he heard running a commentary 
about him, saying he would be a wimp not to ﬁ ght. He was 
urgently hospitalized. He told his mother of a conspiracy 
against him involving the base and hospital personnel who 
gave him drugs that made him sick.
Now in the psychiatrist’s ofﬁ ce, he was calm, without 
suicidal, violent, or homicidal ideas, intent, or plans, but still 
feared for his life. Anthony had no prior acute or chronic ill-
nesses or hospitalizations. There was no history of trauma or 
injury. He denied alcohol or drug abuse, but acknowledged, 
as did his mother, that for the ﬁ rst three months of the year 
prior to going to boot camp, he had joined the “wrong crowd” 
and used a “lot of weed.” He had no problems with the law. 
He failed the ﬁ rst marking period in school that year, some-
thing very uncharacteristic since he was used to being an A 
student. With mother’s approval he had decided to join the 
Army to get away. 
Anthony was born to term in a Spanish-speaking South 
American country. His parents separated soon thereafter 
and his mother relocated to New York where another family 
member had settled. Anthony developed without trouble, as 
his mother struggled to establish herself, and married again 
a couple of years later to a man who was kind to Anthony. 
Anthony traveled to South America yearly to spend time with 
his father who died soon before his trouble in school began. 
His father was “an alcoholic” who had hospitalizations for 
medical, surgical, and psychiatric problems as he got older. 
The mother could recall no history of psychiatric disorders 
in her side of the family.
A physical exam and laboratory tests yielded no 
pathological ﬁ ndings. Anthony did not use prescribed or 
over-the-counter medicines. Alcohol blood level and urine 
toxicology for all drugs of abuse were negative.
Understanding and treating Anthony
Anthony’s history is, in most respects, a clear case of schizo-
phrenia. Some of his behavioral difﬁ culties (eg, lack of 
initiative, inability to plan) suggest diminished functioning of 
the prefrontal cortex. He is alert, fully oriented, and has aver-
age intelligence and intact memory in all spheres. However, 
his thinking, insight, judgment, emotions, perception, and 
behavior are seriously impaired. Anthony used a “lot of 
weed” for three months, about one year prior to the clear onset 
of symptoms. Though no clear causative relationship has 
been established – and none is suggested here – cannabis use 
has been correlated with earlier age of onset of schizophrenia, 
and has been suggested to play a role in its development 
(Bersani et al 2002), the illness often coursing with negative 
symptoms. Anthony’s treatment regimen consisted of atypi-
cal antipsychotic medication to address both his positive and 
signiﬁ cant negative symptoms and supportive psychotherapy 
to stabilize him emotionally, and to help him adhere to the 
treatment regimen, and attend to important matters such as 
family life, ﬁ nances, and obtaining and maintaining a job.
In most cases, the administration of atypical antipsychot-
ics in proper doses, should be the centerpiece of the standard 
for long term care of persons with schizophrenia, a rationale 
applied to the case above. In fact, in a 50 week, open-label 
trial, long-acting risperidone in injectable form  was effec-
tive in ameliorating schizophrenic symptoms (Docherty 
et al 2007). Also, the use of atypical antipsychotics has 
been demonstrated to reinforce participation in long-term 
psychosocial counseling, corresponding with greater efﬁ cacy 
of overall treatment and improved quality-of-life (Rosenheck 
et al 1998). In spite of this, one ought not to discount the 
potentially serious side effects of atypicals, with which one 
must become familiar so as to choose the most adequate 
among drugs of the class for each speciﬁ c case. It is important 
to note that risperidone acts like an atypical in lower doses 
but more like a typical at the upper end of the prescribing 
range (Williams 2001).
Cocaine psychosis: an overview
Among the substances of abuse, cocaine is second only 
to alcohol in number of emergency room visits, hospital 
admissions, and generation of social problems, including 
family violence. The lure for its use is intense euphoria and 
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increased sexual desire and performance, both transient. The 
down side is intense post-cocaine dysphoria, and compulsion 
for further use. 
Cocaine intoxication often courses with anorexia, 
insomnia, anxiety, motor hyperactivity, and “speeded” 
thinking and speech. There is increased adrenergic tonus, 
manifested by diaphoresis, dilated but reactive pupils, hyper-
reﬂ exia, and tachycardia. Stereotypical movements of face, 
mouth, and extremities and even grand mal seizures may be 
present. Local damage inﬂ icted by cocaine depends on the 
route of administration and includes rhinitis, when snorted, 
and bronchitis, when inhaled as free-base. The situation may 
escalate to hypertensive crises, hyperpyrexia, stroke, myocar-
dial infarction, situations that may require heroic emergency 
room measures aimed at preventing death. Cocaine psychosis 
is another consequence of cocaine abuse also commonly 
seen, especially in emergency rooms (Satel and Edell 1991; 
Mendoza et al 1992; Taylor and Staby 1992; Tueth 1993; 
Schwarz et al 1998). 
A person with the above presentation may not furnish a 
reliable history. Thus, before laboratory conﬁ rmation is at 
hand, it is useful to bear in mind that cocaine- and amphet-
amine-induced psychoses may be clinically indistinguishable 
and their differential diagnosis with schizophrenia, difﬁ cult. 
Cocaine use becomes a chronic pattern of a few days’ heavy 
binge followed by a “crash.” The person is often anhedonic, 
irritable, anxious, and has low-key mood. Since it is asso-
ciated with heavy use, cocaine psychosis is considered an 
episodic event.
Preclinical research has shown that cocaine acts in pre-
synaptic nigrostriatal and mesolimbic dopamine pathways, 
by both blocking transporter reuptake and enhancing release 
mechanisms, thus increasing neurotransmission (de Wit and 
Wise 1977; Church et al 1987; Ritz et al 1987; Bradberry and 
Roth 1989; Hurd and Ungerstedt 1989; Kalivas and Duffy 
1990; Broderick 1991a, 1991b, 1992a, 1992b; Broderick 
et al 1993). It is thought that increased neurotransmission 
in mesolimbic and mesocorticolimbic dopamine reward 
pathways emanates from the ventral tegmental area (Roberts 
and Koob 1982; Goeders and Smith 1983; Evenden and 
Ryan 1988; Einhorn et al 1988; Kalivas 1993; Broderick 
and Phelix 1997). 
In addition to its established effects on dopamine levels, 
cocaine has been demonstrated to stimulate increased sero-
tonin release in the nucleus accumbens (Broderick et al 1993; 
Bradberry et al 1993). In fact, serotonin has been implicated 
in cocaine’s electrophysiological, transporter, behavioral, 
and reinforcing effects (Cunningham and Lakoski, 1988; 
Broderick 1991b, 1992a, 1992b, 2002; Carroll et al 1993; 
Hall et al 2002). Mesolimbic and nigrostriatal serotonin 
release increased rhythmic movement during animal natural 
exploration whereas cocaine disrupted this rhythmic balance 
(Broderick 2002). 
We have focused on serotonin-dopamine interactions to 
explain cocaine’s neurochemical and behavioral properties. 
The literature shows that cocaine increases dopamine prob-
ably through serotonin 
2C
 receptor action that is postsynapti-
cally mediated. Also, adjunct mechanisms, such as feedback 
compensatory mechanisms from the ventral tegmental area 
provide additional dopamine release presynaptically by using 
serotonin 
2A
 (Filip and Cunningham 2002). 
The evidence heavily favors the involvement of dopamine-
serotonin interactions in the mechanism of action of cocaine: 
1) Immunohistochemical studies (Steinbusch 1981) and 
immunocytochemical studies (Broderick and Phelix 1997). 
The latter study shows that ventral tegmental dopamine cell 
bodies contain a dense network of serotonin axonal varicosi-
ties. 2) Phelix and Broderick (1995) showed extensive overlap 
of dopamine and serotonin axons in core and shell, through 
neuroanatomic localization of tyrosine hydroxylase- and 
serotonin-containing axons in nucleus accumbens. 3) Herve 
and colleagues (1987) have shown that serotonin neurons 
innervate dopamine neurons synaptically, through light- and 
electron microscopy-derived ultra structural evidence. 4) Van 
Bockstaele and Pickel (1993), Van Bockstaele and colleagues 
(1994), Broderick and Phelix (1997) have produced cellular 
evidence for serotonergic excitation of dopamine neurons. 
Thus, serotonergic dopamine modulation plays a key role in 
shaping the neurochemical proﬁ le of cocaine use, and is addi-
tionally an efﬁ cacious target for atypical antipsychotic therapy. 
Indeed, critical evidence from the Broderick research labora-
tory has recently shown that a biochemically deﬁ cient animal, 
deﬁ cient in dopamine and serotonin in nucleus accumbens, is 
unable to react to the administration of the psychostimulant 
cocaine (Broderick and Hope 2006).
Cocaine psychosis: a clinical case
MA, a 29-year-old male came into the ER on a Tuesday at 
3:00 am, brought by the Emergency Medical Service ambulance, 
after calling 911, himself. He complained of hearing voices 
telling him to jump in front of the subway. Afraid he might 
do it, he called the ambulance. He had been “binging” with 
friends “snorting cocaine, and smoking crack” from the previ-
ous Friday after work until late Monday evening, missing work 
in the process. He felt “paranoid” that evening around 10:00 
pm. He was sure, then, he had been followed all day long by 
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a Maﬁ a gangster intent on killing him. He tried to escape from 
the gangster but saw him, through the corner of his eye, hide in 
his girlfriend’s apartment building as MA arrived hoping to be 
allowed to “crash” in his girlfriend’s apartment. MA rang the 
bell, but glancing at him from the inside, the girlfriend did not 
open the door. He immediately “understood” she had betrayed 
him with the gangster. He went to his parents’ home next but 
was turned away. By then he was thoroughly convinced that 
there was a wide plot against him. Voices in his head started 
commanding him to kill himself. MA roamed the streets where 
he got into a “couple” of shouting matches over “nonsense” with 
fellow street dwellers. He next went to a friend’s house and tried 
to sleep. Again the voices shouted at him insistently and, fearful 
he would end up obeying them and killing himself, he called 
911. During his ER evaluation, MA had a wild appearance. 
He was disheveled and dirty, in a very poor state of hygiene. 
Although constitutionally thin, he looked like he had lost some 
weight and appeared dehydrated. He looked and behaved in a 
suspicious manner and his attitude toward the examiner was 
guarded, somewhat hostile, and marginally cooperative. He was 
also “scared” and expressed that feeling as pervasive. His affect 
was constricted but appropriate to the content of his thinking. 
He was alert, fully oriented and his memory was intact. He was 
distracted, his speech was rapid, and he was delusional. His in-
sight was poor and his judgment uneven. He was treated in the 
ER with intra-muscular combination of haloperidol (a typical 
antipsychotic), lorazepam (an anti-anxiety benzodiazepine), and 
diphenhydramine (antihistamine with sedative effects). He slept 
for many hours, but upon awakening, MA was still psychotic, 
which prompted psychiatric hospitalization. On the ward, he was 
switched to an atypical antipsychotic. 
MA has a long history of cocaine-related incidents includ-
ing ER visits, brushes with the law, rough-handling of his 
girlfriend, and one instance in which he pushed and shoved 
his parents, causing injuries that were not life threatening, 
but necessitated medical attention. His girlfriend broke up 
with him two months later, when she saw his cocaine use was 
again escalating after a hiatus; he snorted cocaine occasion-
ally during this hiatus. His parents have closed their doors 
to him for the same reason as did his girlfriend. He recently 
lost his apartment because he used rent money to feed his 
habit. He shuttled for shelter among cocaine-abusing friends’ 
apartments. Exacerbating this chaos in his life, he is on the 
verge of losing his job due to erratic attendance patterns.
Understanding and treating MA
As can be seen in MA’s case, cocaine-induced psychosis 
(Brady et al 1991) is the most severe psychiatric consequence 
of abuse. It often courses with persecutory delusions, 
auditory, visual, and tactile hallucinations, the latter, of tiny 
insects crawling on one’s skin, called formication. Rosse 
and colleagues (1994) likened cocaine-induced “paranoia” 
to that of schizophrenia. In fact, SPECT studies show that 
cocaine-induced changes in blood ﬂ ow are similar to those 
found in schizophrenic persons (Miller et al 1992). Animal 
models of cocaine psychosis have long demonstrated that: 
1) psychostimulant behavior depends on dopaminergic 
nigrostriatal neuronal pathways (Cools and van Rossum 
1970; Costall and Naylor 1973; Wise and Bozarth 1987; 
Broderick 2002); 2) dopamine antagonists block psycho-
stimulant behavior (Pijnenburg et al 1975). 
Psychostimulant-induced neurochemistry and behavior 
have become an accepted animal model of certain aspects 
of psychoses. This is supported by these ﬁ ndings: 1) Typical 
antipsychotics, known to block mesolimbic and nigrostriatal 
dopamine, reduce psychotic symptoms in humans via meso-
limbic pathways, but produce movement disorders through 
nigrostriatal circuits (Gawin and Kleber 1986; Kleber and 
Gawin 1986). 2) Atypical antipsychotic agents, known to act 
on mesolimbic/mesocorticolimbic dopaminergic neuronal 
pathways (Huff and Adams 1980), reduce both positive and 
negative psychotic symptoms in humans (Meltzer 1989). 
We have noted earlier that atypicals are quite effec-
tive in the management of schizophrenia. In fact, the use 
of risperidone also has shown promise in cocaine abusing 
schizophrenic persons (Tsuang et al 2002); in controlling 
craving for cocaine (Smelson et al 2002); on cocaine-in-
duced euphoria (Newton et al 2001), on cocaine dependence 
(Grabowski et al 2000); and on cue-elicited craving for 
cocaine (Smelson et al 1997). Broderick and colleagues 
(2003) have studied the effects of risperidone on cocaine in 
the psychostimulant animal model of psychosis and we have 
proceeded further with new neuromolecular imaging (NMI) 
research in this area as shown in this paper in Figures 1–3. 
NMI, with nationally and internationally patented, miniature 
BRODERICK PROBE® sensors and real time electrochemi-
cal detection, is cutting-edge research. NMI is conducted 
concomitantly and simultaneously with infrared detection 
of locomotor (ambulatory) behavioral measurements. This 
research has led to the following conclusions: 1) Cocaine 
produced withdrawal symptoms in subacute studies, probably 
due to neuroadaptive mechanisms, especially in dopamine 
and serotonin release in nucleus accumbens. 2) Risperidone 
acutely blocked cocaine-enhanced neurochemistry and 
behavior, and subacutely improved cocaine’s withdrawal 
effects on accumbens neurochemistry. 3) Risperidone thus 
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Figure 1A Day 1 The effect of cocaine (10 mg/kg i.p.) on adult, male Sprague-Dawley laboratory rats (n = 4). Studies were done with neuromolecular imaging (NMI) based on 
in vivo electrochemistry. The imaging was performed with the BRODERICK PROBE® sensors. Sensors were implanted in NAcc and verifi ed by the blue dot perfusion method. 
DA and 5-HT were detected selectively in the freely moving animal (concurrent behavioral data are presented below). Cocaine increased DA release in NAcc up to 75% over 
baseline (unpaired t-test, p < 0.0001 compared with preadministration), and increased 5-HT by 190% over baseline (unpaired t-test p < 0.0001 compared with baseline).
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Figure 1B Day 2 Withdrawal effects after a single injection of cocaine (10 mg/kg i.p.) in adult, male Sprague-Dawley laboratory rats (n = 4) measured one day after prior 
administration. Studies were performed with the same paradigm as described in Figure 1A. Withdrawal effects were as follows: DA was signifi cantly decreased from baseline 
(unpaired t-test p < 0.0001) and 5-HT was higher than at baseline only at the fi rst point likely due to “novelty chamber effects” (unpaired t-test p < 0.05). Moreover, both 
DA and 5-HT were signifi cantly lower than their Day-1 post-cocaine administration levels (unpaired t-test p < 0.0001).
482
Nunes and Broderick
Neuropsychiatric Disease and Treatment 2007:3(4)
Figure 2A Day 1 The effect of co-administration of risperidone (2mg/kg s.c.) and cocaine (10 mg/kg i.p.) on adult, male Sprague-Dawley laboratory rats (n = 4). 5-HT 
release in NAcc after administration of risperidone and cocaine combination, did not signifi cantly differ from baseline values (p = 0.415, unpaired t-test). As evidenced by 
Naiker, et al, 2mg/kg risperidone in the male laboratory rat is equivalent to a low-dose of single risperidone treatment in human psychotic patients. Furthermore, 5-HT 
release was found to be signifi cantly lower when risperidone was administered with cocaine compared with cocaine alone (unpaired t-test, p < 0.0001). DA release was 
signifi cantly different from its baseline upon co-administration (unpaired t-test, p < 0.05). Importantly, effects of risperidone and cocaine on DA release in NAcc was signifi -
cantly decreased (p < 0.0001) from cocaine effects on DA release when cocaine was given alone.
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Figure 2B Day 2 Effects after a single co-administration of risperidone (2 mg/kg s.c.) and cocaine (10 mg/kg i.p.) to adult, male Sprague-Dawley laboratory rats (n = 3). 
Absence of typical withdrawal effects is evident relative to cocaine, as follows: risperidone-cocaine did not differ signifi cantly from baseline on the second day (unpaired 
t-test, p = 0.3285 for 5-HT and p = 0.4433 for DA). Additionally, there was no signifi cant difference between risperidone-cocaine on the fi rst day and on the second day (p 
= 0.2994 for 5-HT and p = 0.0514 for DA). Thus, the data suggest that risperidone may be effective in the treatment of cocaine psychosis both for its impact on negative 
symptoms and its alleviation of acute withdrawal effects from cocaine.
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Figure 3B Day 2 Adult male Sprague-Dawley laboratory rats who received 
cocaine (10 mg/kg i.p.) and co-administered risperidone (2 mg/kg s.c.) and cocaine 
(10 mg/kg i.p.) were monitored one day after drug administration to detect 
possible withdrawal effects with respect to ambulations. Neither cocaine nor 
risperidone showed signifi cant second-day effects over baseline (unpaired t-test, 
p = 0.2478 and p = 0.3605, respectively). 
Note: First point in both groups denotes “novelty to chamber” effects.
may be a viable psychopharmacological tool in the treatment 
of cocaine addiction, withdrawal, and psychosis.
Closing comments on clinical 
management of schizophrenia 
and cocaine abuse
We have shown that this novel research points toward the useful-
ness of atypical antipsychotic agents in the treatment of schizo-
phrenia and cocaine-related disorders. While the usefulness of 
atypical antipsychotic agents is well established in the treatment 
of schizophrenia, the potential usefulness of these agents remains 
very good in the treatment of cocaine-related disorders. 
Again, because schizophrenia and cocaine abuse are 
multifaceted conditions, no simple solution exists for their 
clinical management. While reliance on established treatment 
guidelines and best practices is the optimal modus operandi, 
clinicians must assess patient presentation to institute the 
proper individually-tailored management strategy. We strongly 
advocate that clinicians add to their management strategies 
the most direct conclusions of research, such as that reported 
herein, whose mechanisms and hypotheses are sound. These 
novel translated research ﬁ ndings can add an important dimen-
sion to clinical protocol-building and provide up-to-the-minute 
potential solutions to difﬁ cult problems.
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